| Literature DB >> 30513970 |
Hae-Ryeon Choi1, Jinmin Kim2, Hyojung Lim3, Yoo Kyoung Park4.
Abstract
The ketogenic diet has long been recommended in patients with neurological disorders, and its protective effects on the cardiovascular system are of growing research interest. This study aimed to investigate the effects of two-week of low-calorie ketogenic nutrition drinks in obese adults. Subjects were randomized to consume drinks either a ketone-to-non-ketone ratio of 4:1 (KD 4:1), a drink partially complemented with protein at 1.7:1 (KD 1.7:1), or a balanced nutrition drink (BD). Changes in body weight, body composition, blood lipid profile, and blood ketone bodies were investigated. Blood ketone bodies were induced and maintained in the group that consumed both 4:1 and 1.7:1 ketogenic drinks (p < 0.001). Body weight and body fat mass significantly declined in all groups between 0 and 1 week and between 1 and 2 weeks (p < 0.05), while skeletal muscle mass remained unchanged only in the KD 1.7:1 group (p > 0.05). The blood lipid profile improved, appetite was reduced, and fullness was maintained in the two ketogenic drink groups. This study indicates the possibility for the development of obesity treatments based on ketogenic nutrition drinks even with a moderate ketogenic ratio of 1.7:1, as well as adjuvant therapies based on ketosis induction and maintenance for the treatment of other diseases and health conditions.Entities:
Keywords: food for special dietary use; ketogenic diet; nutrition drink; obesity; weight loss
Mesh:
Substances:
Year: 2018 PMID: 30513970 PMCID: PMC6316485 DOI: 10.3390/nu10121895
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Composition of nutrition drinks.
| KD4:1 (1) | KD1.7:1 (2) | BD (3) | |
|---|---|---|---|
| Energy (kcal) | 200 | 200 | 200 |
| C:P:F (% of kcal) (4) | 3:7:90 | 4:16:80 | 54:16:30 |
| Carbohydrate (g) (5) | 1.7 | 2.3 | 28.0 |
| Fiber (g) (6) | 0.0 | 0.7 | 1.0 |
| Protein (g) (7) | 3.3 | 8.0 | 8.0 |
| Fat (g) (8) | 20.0 | 17.7 | 7.0 |
| Saturated fat (g) (9) | 4.2 | 0.0 | 2.0 |
(1) KD4:1 = Ketogenic nutrition drink 4:1 (Ketonina, Namyang Dairy Product Co Ltd., Seoul, Korea). (2) KD1.7:1 = Ketogenic nutrition drink 1.7:1 (Product for research, Maeil Dairies Co Ltd., Gyeonggi-doKorea). (3) BD = Balanced nutrition drink (Mediwell Nutty flavor, Maeil Dairies Co Ltd., Gyeonggi-do, Korea). (4) C:P:F = Carbohydrate:Protein:Fat (% of kcal). (5) KD4:1 = Maltodextrin, white sugar; KD1.7:1 = Maltodextrin, white sugar; BD = Maltodextrin, white sugar. (6) KD4:1 = Soybean fiber; KD1.7:1 = Soybean fiber, non-digestible maltodextrin/indigestible maltodextrin; BD = Soybean fiber. (7) KD4:1 = Sodium caseinate, milk fat globule membrane protein; KD1.7:1 = Sodium caseinate, isolated soy protein; BD = Sodium caseinate, isolated soy protein. (8) KD4:1 = Pure olive oil (extra virgin olive oil, δ tocopherol (mixed)), edible oils and fats (soybean oil, high oleic sunflower oil, coconut oil, δ tocopherol (mixed)), canola oil; KD1.7:1 = High oleic sunflower oil (3.7%), canola oil (3.7%); BD = Canola oil (3%). (9) KD4:1 = Medium Chain Triglyceride (MCT) oil; KD1.7:1 = MCT oil (3.3%); BD = MCT oil (0.006%).
Figure 1Diagram of study flow. (1) KD4:1 = Ketogenic nutrition drink 4:1 (Ketonina, Namyang Dairy Product Co Ltd., Seoul, Korea). (2) KD1.7:1 = Ketogenic nutrition drink 1.7:1 (Product for research, Maeil Dairies Co Ltd., Gyeonggi-doKorea). (3) BD = Balanced nutrition drink (Mediwell Nutty flavor, Maeil Dairies Co Ltd., Gyeonggi-do, Korea).
Baseline characteristics of the study participants.
| Variables | KD4:1 (3) ( | KD1.7:1 (4) ( | BD (5) ( | |
|---|---|---|---|---|
| Age (years) | 29.5 ± 9.0 (1) | 24.5 ± 4.8 | 26.0 ± 7.5 | 0.141 |
| Sex (%) | ||||
| Female | 4 (30.8) (2) | 5 (38.5) | 4 (36.4) | 0.739 |
| Male | 9 (69.2) | 8 (61.5) | 7 (63.6) | |
| Height (cm) | 170.3 ± 12.4 | 169.9 ± 10.0 | 171.1 ± 7.6 | 0.962 |
| Body composition | ||||
| Body water (L) | 41.8 ± 8.9 | 41.1 ± 9.1 | 41.7 ± 7.9 | 0.974 |
| Protein (kg) | 11.3 ± 2.5 | 11.2 ± 2.5 | 11.3 ± 2.2 | 0.975 |
| Mineral (kg) | 4.0 ± 0.9 | 4.0 ± 0.9 | 4.0 ± 0.7 | 0.998 |
| Body weight (kg) | 87.3 ± 17.1 | 82.9 ± 14.3 | 85.8 ± 14.8 | 0.764 |
| Skeletal muscle (kg) | 32.2 ± 7.4 | 31.6 ± 7.6 | 32.1 ± 6.5 | 0.974 |
| Body fat mass (kg) | 30.2 ± 10.1 | 26.7 ± 7.3 | 28.8 ± 7.6 | 0.862 |
| BMI (kg/m2) (6) | 30.0 ± 4.2 | 28.5 ± 2.8 | 29.2 ± 4.0 | 0.779 |
| Waist circumference (cm) | 100.0 ± 11.3 | 94.2 ± 7.3 | 96.3 ± 10.1 | 0.318 |
| Hip circumference (cm) | 107.9 ± 7.5 | 108.6 ± 6.2 | 108.7 ± 7.2 | 0.950 |
| Blood lipid profile | ||||
| Total cholesterol (mg/dL) | 184.9 ± 31.2 | 179.8 ± 30.2 | 182.8 ± 28.9 | 0.912 |
| Triglyceride (mg/dL) | 142.4 ± 69.6 | 106.2 ± 45.8 | 101.5 ± 63.4 | 0.218 |
| LDL cholesterol (mg/dL) (7) | 116.2 ± 28.4 | 111.4 ± 31.3 | 120.3 ± 23.3 | 0.742 |
| HDL cholesterol (mg/dL) (8) | 50.8 ± 9.5 | 57.9 ± 11.7 | 52.6 ± 16.0 | 0.331 |
(1) Values are means ± SD; (2) Values are N (%); (3) KD4:1 = Ketogenic nutrition drink 4:1; (4) KD1.7:1 = Ketogenic nutrition drink 1.7:1; (5) BD = Balanced nutrition drink; (6) BMI = Body mass index; (7) LDL = Low-density lipoprotein; (8) HDL = High-density lipoprotein; (9) Significantly different at p < 0.05 by chi-square test, Fisher’s exact test, ANOVA test, or Kruskal–Wallis test.
Daily dietary intake in each group during two weeks of intervention.
| KD4:1 (2) ( | KD1.7:1 (3) ( | BD (4) ( | ||
|---|---|---|---|---|
| Energy (kcal) | 1159.1 ± 416.1 (1) | 1280.8 ± 262.2 | 1357.1 ± 292.5 | 0.583 |
| Energy deficit (5) | 799.7 ± 373.2 | 743.8 ± 157.5 | 716.2 ± 94.4 | 0.765 |
| Carbohydrate (g) | 9.7 ± 3.5 c | 14.5 ± 3.0 b | 190.0 ± 40.9 a | 0.000 |
| Fiber (g) | 0.0 ± 0.0 c | 4.3 ± 0.9 b | 6.8 ± 1.5 a | 0.000 |
| Protein (g) | 19.3 ± 6.9 b | 51.2 ± 10.5 a | 54.3 ± 11.7 a | 0.000 |
| Fat (g) | 115.9 ± 41.6 a | 113.6 ± 23.2 a | 47.5 ± 10.2 b | 0.000 |
| Saturated fat (g) | 24.1 ± 8.7 a | 0.0 ± 0.0 c | 13.6 ± 2.9 b | 0.000 |
(1) Values are means ± SD; (2) KD4:1 = Ketogenic nutrition drink 4:1; (3) KD1.7:1 = Ketogenic nutrition drink 1.7:1; (4) BD = Balanced nutrition drink; (5) Deficit of energy requirements and energy intake; (6) Values with different letters in a column indicate statistically significant difference using Kruskal–Wallis test by Mann–Whitney U test (p < 0.05 ).
Changes in anthropometry and body composition by each group.
| KD4:1 (2) | KD1.7:1 (3) | BD (4) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Δ1 week-0 week (5) ( | Δ2 week-1 week (6) ( | Δ2 week-0 week (7) ( | Δ1 week-0 week (5) ( | Δ2 week-1 week (6) ( | Δ2 week-0 week (7) ( | Δ1 week-0 week (5) ( | Δ2 week-1 week (6) ( | Δ2 week-0 week (7) ( | |
| Body water (L) | −2.2 ± 1.3 ∫(1) | −0.5 ± 0.8 | −2.8 ± 1.1 ∫ | −1.1 ± 1.4 † | −0.3 ± 1.0 | −1.5 ± 1.1 ‡ | −1.2 ± 0.7 ∫ | −0.3 ± 0.5 | −1.5 ± 0.8 ∫ |
| Protein (kg) | −0.5 ± 0.3 ∫ | −0.2 ± 0.2 † | −0.7 ± 0.3 ∫ | −0.3 ± 0.4 | −0.1 ± 0.3 | −0.4 ± 0.3 ‡ | −0.3 ± 0.2 ∫ | −0.1 ± 0.2 † | −0.4 ± 0.2 ∫ |
| Mineral (kg) | −0.2 ± 0.1 ∫ | −0.0 ± 0.1 | −0.3 ± 0.1 ‡ | −0.1 ± 0.1 † | −0.0 ± 0.1 | −0.2 ± 0.1 ∫ | −0.1 ± 0.1 ∫ | −0.1 ± 0.1 | −0.2 ± 0.1 ‡ |
| Body weight (kg) | −3.9 ± 1.4 ∫ | −1.7 ± 0.7 ∫ | −5.9 ± 1.8 ∫ | −3.3 ± 1.2 ∫ | −1.0 ± 1.1 † | −4.4 ± 1.5 ∫ | −2.3 ± 1.0 ∫ | −1.1 ± 0.7 ∫ | −3.4 ± 1.3 ∫ |
| Skeletal muscle (kg) | −1.5 ± 1.0 † | −0.4 ± 0.5 † | −2.1 ± 0.8 ∫ | −0.7 ± 1.2 | −0.3 ± 0.8 | −1.0 ± 1.0 ‡ | −0.9 ± 0.5 ∫ | −0.3 ± 0.4 † | −1.2 ± 0.6 ∫ |
| Body fat mass (kg) | −1.1 ± 1.0 † | −1.0 ± 0.8 ‡ | −2.2 ± 1.4 ∫ | −1.8 ± 2.0 ‡ | −0.5 ± 0.8 † | −2.5 ± 1.9 ‡ | −0.8 ± 0.5 ‡ | −0.6 ± 0.6 † | −1.3 ± 0.7 ‡ |
| BMI (kg/m2) (8) | −1.4 ± 0.5 ∫ | −0.5 ± 0.2 ∫ | −2.1 ± 0.6 † | −1.1 ± 0.4 ∫ | −0.3 ± 0.4 † | −1.5 ± 0.5 ∫ | −0.8 ± 0.3 ‡ | −0.4 ± 0.3 ‡ | −1.2 ± 0.4 ‡ |
| Waist circumference (cm) | −3.5 ± 2.5 ∫ | −1.4 ± 1.7 | −4.8 ± 2.1 ∫ | −3.7 ± 2.6 ∫ | −0.8 ± 2.2 | −4.6 ± 3.9 ‡ | −3.0 ± 1.9 ‡ | −1.5 ± 1.7 † | −4.5 ± 2.0 ‡ |
| Hip circumference (cm) | −2.0 ± 1.8 ‡ | −2.0 ± 1.5 ‡ | −3.9 ± 2.0 ‡ | −1.8 ± 1.8 ‡ | −1.1 ± 0.9 ‡ | −3.1 ± 1.0 ∫ | −1.2 ± 0.8 ‡ | −0.9 ± 1.5 | −2.1 ± 1.6 ‡ |
(1) Values are means ± SD, Significance as determined by Paired t-test, Wilcoxon signed rank test. p-value less than † p < 0.05, ‡ p < 0.01, ∫ p < 0.001.; (2) KD4:1 = Ketogenic nutrition drink 4:1; (3) KD1.7:1 = Ketogenic nutrition drink 1.7:1; (4) BD = Balanced nutrition drink; (5) Difference between 1 week and 0 week; (6) Difference between 2 weeks and 1 week; (7) Difference between 2 weeks and 0 week; (8) BMI = Body mass index.
Changes in blood lipids by group.
| KD4:1 (2) | KD1.7:1 (3) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Δ1 week-0 week (5) ( | Δ2 week-1 week (6) ( | Δ2 week-0 week (7) ( | Δ1 week-0 week (5) ( | Δ2 week-1 week (6) ( | Δ2 week-0 week (7) ( | ||||
| Total cholesterol (mg/dL) | 2.5 ± 21.9 (1) | −23.0 ± 15.1 ‡ | −18.3 ± 22.0 | 1.3 ± 18.9 | −18.9 ± 18.2 ‡ | −14.0 ± 13.9 ‡ | 2.6 ± 16.0 | −14.6 ± 17.2 † | −11.9 ± 15.2 † |
| Triglyceride (mg/dL) | −18.4 ± 99.9 | 7.4 ± 57.8 | −27.7 ± 43.9 | −7.9 ± 44.3 | −5.0 ± 30.1 | −14.3 ± 33.9 | −8.4 ± 44.6 | 7.2 ± 22.6 | −1.2 ± 40.9 |
| LDL cholesterol (mg/dL) (8) | 8.2 ± 20.6 | −24.5 ± 15.3 ‡ | −11.6 ± 22.6 | 3.4 ± 17.4 | −15.5 ± 18.2 † | −9.6 ± 13.2 † | 4.6 ± 13.9 | −15.0 ± 14.8 ‡ | −10.4 ± 9.2 ‡ |
| HDL cholesterol (mg/dL) (9) | −1.5 ± 10.6 | 0.6 ± 6.8 | −0.6 ± 13.7 | −2.8 ± 5.9 | −0.1 ± 3.8 | −2.3 ± 3.8 | −0.8 ± 6.8 | −2.9 ± 3.2 † | −3.7 ± 8.2 |
(1) Values are means ± SD, Significance as determined by Paired t-test, Wilcoxon signed rank test. p-value less than † p < 0.05, ‡ p < 0.01; (2) KD4:1 = Ketogenic nutrition drink 4:1; (3) KD1.7:1 = Ketogenic nutrition drink 1.7:1; (4) BD = Balanced nutrition drink; (5) Difference between 1 week and 0 week; (6) Difference between 2 weeks and 1 week; (7) Difference between 2 weeks and 0 week; (8) LDL = Low density lipoprotein; (9) HDL = High density lipoprotein.
Figure 2Changes in ketone body biomarkers of each group at 0 week, 1 week, and 2 weeks. †† Significant difference between 0 week and 1 week by Paired t-test, Wilcoxon signed rank test. ‡‡ Significant difference between 1 week and 2 weeks by Paired t-test, Wilcoxon signed rank test. § Significant difference between 0 week and 2 weeks by Paired t-test, Wilcoxon signed rank test.
Figure 3Changes in symptom scores (side effects) reported by each group. †† Significant difference between 0 week and 1 week by Paired t-test, Wilcoxon signed rank test; § Significant difference between 0 week and 2 weeks by Paired t-test, Wilcoxon signed rank test.